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Abstract: 39 
Objective. Most women with ovarian cancer relapse and undergo further chemotherapy 40 
however evidence regarding the benefits of this for women with platinum-resistant disease is 41 
limited. Our objective was to determine whether there was a quality of life improvement or 42 
treatment response among women treated for platinum-resistant recurrent ovarian cancer.  43 
Methods. We combined data from 2 studies where women treated with chemotherapy for 44 
recurrent ovarian cancer (n=172) completed a quality of life questionnaire every 3 months. 45 
Cancers were classified as platinum-resistant if they progressed within 6 months of 46 
completing first-line chemotherapy. Mixed effects models were used to analyse change in 47 
quality of life during the first 6 months after second-line chemotherapy. 48 
Results. One-quarter of women (n=44) were classified as having platinum-resistant disease. 49 
Overall, their quality of life did not significantly increase or decrease, following 50 
commencement of second-line chemotherapy (least square mean scores = 107, 105, 103 at 51 
chemotherapy start, 3 and 6 months later, respectively), although 26% of these women 52 
reported a meaningful increase and 31% reported a meaningful decline. One-third of the 53 
platinum-resistant group responded (11% complete and 21% partial response) to second-line 54 
chemotherapy, and this figure increased to 54% among the subset (36%) re-treated with 55 
platinum-based agents with or without other agents. Preliminary analyses suggest quality of 56 
life may be higher at chemotherapy initiation in women whose disease responded (median 57 
score 121 vs 110).  58 
Conclusions. Overall, quality of life appears to be maintained in women with platinum-59 
resistant ovarian cancer who receive further chemotherapy and some women respond to re-60 
treatment. 61 
Keywords:  ovarian cancer, oncology, progression, recurrence, chemotherapy, platinum-62 
resistance, quality of life 63 
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 64 
Introduction 65 
 66 
Ovarian cancer is the fifth most common cause of cancer death in women [1]. Two-thirds of 67 
women diagnosed with ovarian cancer present with advanced disease and, although most 68 
initially respond to treatment, the vast majority eventually experience disease progression [2]. 69 
With few exceptions, recurrent ovarian cancer is not curable, yet end-points of most clinical 70 
trials in this group include response to treatment, progression-free survival and overall 71 
survival. In such a palliative setting, quality of life may be a more meaningful end-point.   72 
 73 
After first-line chemotherapy for ovarian cancer, time to progression can be used to predict 74 
how groups of patients might respond to further chemotherapy at relapse [3]. A cancer with a 75 
long progression-free interval after completion of chemotherapy (>6 months) is associated 76 
with higher response rates to re-treatment, and is classified as ‘platinum-sensitive’. 77 
Management of recurrent disease in this group generally involves further platinum-based 78 
chemotherapy with response rates ranging from 30-60% and a median progression-free 79 
survival of 6-12 months [4, 5].  80 
 81 
Women whose disease progresses within 6 months of completing first-line chemotherapy are 82 
defined as having ‘platinum-resistant’ disease. They have a 10-25% likelihood of responding 83 
to second-line chemotherapy, a median progression-free survival of 3.5-4 months and a 84 
median overall survival of 9-10 months [4, 6]. ‘Platinum-refractory’ disease refers to disease 85 
that progresses during chemotherapy and the objective response rate to second-line 86 
chemotherapy in these patients is <10% [4]. While a subset of women in these groups derive 87 
a survival benefit from second-line chemotherapy, some women with platinum-88 
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resistant/refractory ovarian cancer continue to receive aggressive and expensive 89 
chemotherapy until days before their death [7]. The goal of end of life care is to maximize 90 
quality of life yet to date only 1 small study (n=9 with complete data) with a highly selected 91 
patient group of women with good performance status, has considered quality of life 92 
specifically among women with platinum-resistant recurrent ovarian cancer [8]. Other studies 93 
which have combined women with platinum-sensitive and resistant disease, found quality of 94 
life improvements after chemotherapy [9], however these pooled results are likely to be 95 
driven by the high proportion of women with platinum-sensitive disease. We have used 2 96 
population-based longitudinal datasets to determine if there is a quality of life improvement 97 
following second-line chemotherapy among women with platinum-resistant ovarian cancer 98 
and have compared this group to women with platinum-sensitive disease. We also consider 99 
treatment response among these subgroups.   100 
 101 
Methods 102 
 103 
Study designs 104 
 105 
We combined data from 2 longitudinal studies of women with ovarian cancer (Figure 1). 106 
Ethics approval was obtained from the Human Research Ethics Committees of the QIMR 107 
Berghofer Medical Research Institute, The University of Sydney and all participating 108 
hospitals. Participants from both studies provided informed consent. 109 
 110 
The first study, PROSPECT [10], recruited 74 women with newly-diagnosed and 48 with 111 
recurrent disease from 7 hospitals in 2 Australian states between April 2003 and January 112 
2005. Eligible patients were women aged 18 to 79 years referred for chemotherapy for 113 
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primary epithelial ovarian cancer and who were able to complete the study documents in 114 
English. Participants were mailed questionnaires every 3 months for 2 years or until they 115 
withdrew or died. At study entry participants were between 1 month and 20 years post-116 
diagnosis (median 15 months).  117 
 118 
The second study included 798 women who had participated in a previous population-based 119 
case-control study [11-13]. The Australian Ovarian Cancer Study (AOCS) recruited women 120 
aged 18–79 years with invasive epithelial ovarian cancer diagnosed between January 2002 121 
and June 2006 through gynaecological oncology units and state-based cancer registries in all 122 
Australian states and territories. Women who participated in AOCS and were still alive 123 
between May 2005 and March 2007 were invited to take part in a quality of life substudy 124 
(AOCS-QoL) [14]. Women who consented were mailed questionnaires at 3-monthly intervals 125 
for up to 2 years, beginning 3 months to 5 years after diagnosis (median 26 months).  126 
 127 
Women from the PROSPECT and AOCS-QoL studies were excluded from this analysis if 128 
they did not experience a progression of their disease during data collection (n=434), or did 129 
not complete a quality of life questionnaire within 2 months of starting chemotherapy for 130 
their first disease progression (n=304, including 2 with platinum-resistant and 7 with 131 
platinum-sensitive disease who did not have further chemotherapy) or if their disease was not 132 
classifiable as platinum-resistant or –sensitive (n=7 of whom 2 were platinum-refractory). We 133 
also removed duplicate data for 3 women who were in both studies leaving 172 women for 134 
analysis.  135 
 136 
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Data collection instruments and classification  137 
 138 
Platinum status and treatment response: We reviewed medical records for date of diagnosis, 139 
start and completion dates of each chemotherapy course and cancer antigen (CA) -125 blood 140 
levels at each follow-up with the treating doctor. Platinum status was classified based on 141 
response to first-line treatment (CA-125 and CT scans when available) [4, 15, 16]. Women 142 
who had at least a partial response to first-line platinum-based chemotherapy and no disease 143 
progression within the first 6 months after completion of chemotherapy, were classified as 144 
platinum-sensitive and those who had no response and/or disease progression within 6 145 
months of completing chemotherapy were classified as platinum-resistant. Response to 146 
chemotherapy after second-line treatment was determined based on CA-125 criteria alone. 147 
That is, compared to a pretreatment CA-125, a complete response was defined as 148 
normalization of CA-125 maintained for 28 days, a partial response was defined as at least a 149 
50% reduction maintained for 28 days and no response was defined as no sustained reduction 150 
in CA-125. 151 
 152 
Quality of Life: This was measured using the 39-item Functional Assessment of Cancer 153 
Therapy—Ovarian (FACT-O). The FACT-O is a multi-dimensional, ovarian cancer-specific 154 
instrument, assessing 4 general sub-scales (physical, social, emotional and functional well-155 
being) plus an ovarian cancer and treatment specific subscale. Overall quality of life is 156 
derived from these 5 subscales. This instrument has undergone extensive reliability and 157 
validity testing showing that internal consistency and test-retest reliability are adequate [17]. 158  159 
Covariates: At baseline we collected self-reported demographic information including: date 160 
of birth, marital status and education level. We also collected clinical data from medical 161 
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records including: International Federation of Gynecology and Obstetrics (FIGO) disease 162 
stage at diagnosis and agents/regimen of each chemotherapy course.  163 
 164 
Survival: Dates of disease progression and death were obtained from medical records. 165 
Clinical follow-up of progression and survival status continued until September 2010 for 166 
PROSPECT and July 2010 for AOCS. Survival time was calculated as the date of death, or if 167 
alive, end of clinical follow-up period, minus the date of first progression.  168 
 169 
Statistical methods 170 
 171 
We analyzed data collected during the first 6 months after second-line chemotherapy. After 172 
this there were fewer than 20 participants remaining per group. For the 14% of woman who 173 
were missing data at the 3 or 6 month data-points yet remained active in the study, we 174 
imputed the value as the average score of the time-points before and after the missing time-175 
point. We documented reasons for dropout and calculated, at each time-point, the proportion 176 
of women who dropped out due to death or incapacity (i.e. not missing completely at random) 177 
by platinum status. To determine the likely effect of missingness [18] we graphed quality of 178 
life scores by patterns of dropout, stratified by platinum status. To determine predictors of 179 
missingness [18] we cross-tabulated the characteristics of those who dropped out versus those 180 
who did not.  181 
 182 
We used descriptive statistics, stratified by platinum status, to calculate the proportion of 183 
women re-treated with different chemotherapy regimens and who had a response to 184 
chemotherapy. Cox regression survival analysis was used to obtain hazard ratios and 95% 185 
confidence intervals for post-progression survival by platinum status after adjustment for age.  186 
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 187 
A mixed effects repeated measures model with a random intercept and random slope was 188 
used to estimate the least squares mean scores of quality of life and wellbeing subscales by 189 
platinum status at baseline (0-2 months after the start of second-line chemotherapy) and 3 and 190 
6 months later. We fitted the model using terms for platinum status, the interaction of 191 
platinum status with time, and covariates including age at progression and whether a woman 192 
was on chemotherapy at the time she completed the quality of life questionnaire. An 193 
unstructured covariance matrix for the random effects was used as it had the best fit for this 194 
dataset. Other key demographic and clinical covariates including marital status, education 195 
level, second-line chemotherapy with a platinum-based drug (yes, no) and second-line 196 
chemotherapy with liposomal doxorubicin (yes, no) were not included in the final models as 197 
they were not significantly associated with quality of life in fully adjusted analyses. Although 198 
not significant, age was retained as a standard covariate. Disease stage at diagnosis was not 199 
included as almost all participants (96%) were classified as late stage.  200 
 201 
We repeated our analyses excluding women (a) who dropped out due to death or incapacity 202 
(n=31) and (b) with baseline data only (n=44), to assess the robustness of the results when 203 
different data distributions were included.  Furthermore, as all models have assumptions 204 
about missing data we also conducted sensitivity analyses by fitting a repeated measures 205 
ANOVA model with last observation carried forward and a weighted generalized estimating 206 
equations model to see if the estimates were different from the mixed effects model. The 207 
results across all models were similar and thus the estimates were deemed robust (data not 208 
shown).      209 
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 210 
Clinically important changes and group differences (±) in outcomes were defined a priori as 211 
follows: 8 for the overall FACT-O scale, 2 for the FACT-O wellbeing subscales and 2.5 for 212 
cancer-specific concerns. These minimal differences were part way between the conservative 213 
half standard deviation guideline [19] and what others have reported as clinically meaningful 214 
differences in the gynecological cancer setting [20]. P-value were considered at the 215 
conventional p<0.05 level. 216 
 217 
Results 218 
 219 
Participants 220 
 221 
On average, women in our analysis were 60 years of age at diagnosis (SD = 10), most (71%) 222 
were married or living with their partner, approximately three-quarters (74%) were classified 223 
as platinum-sensitive and almost all had late stage disease at diagnosis (96%) (Table 1).  224 
 225 
Characterizing missingness 226 
 227 
Forty percent of women dropped out of the study due to death, incapacity, unknown reason or 228 
because they had completed their commitment to the parent study (Figure 1). The proportion 229 
of dropouts due to death or incapacity was lower in the platinum-sensitive group (33%) than 230 
in the platinum-resistant group (75%). Irrespective of platinum status, women who dropped 231 
out for any reason had lower mean quality of life at baseline than those with complete data 232 
(Figure 2). Those who dropped out at the 6-month follow-up had similar absolute changes in 233 
quality of life prior to that time-point to the women with complete data (Figure 2).   234 
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 235 
There were no systematic differences in the characteristics of the 37 women who dropped out 236 
due to study completion or for unknown reasons and the 104 women with complete data 237 
(Table 1). However the 31 women who dropped out due to death or incapacity were less 238 
likely to be platinum-sensitive, less likely to have a partner, had lower baseline quality of life 239 
and had shorter survival time compared to those with complete data (Table 1).  240 
 241 
Second-line chemotherapy agents, responses and survival by platinum-status  242 
 243 
Most women (87%, n=111) with platinum-sensitive disease were re-treated with a platinum-244 
based regimen (Figure 3). Approximately one-third (36%, n=16) of women with platinum-245 
resistant disease were re-treated with platinum with or without other chemotherapy agents, 246 
while just under half (43%, n=19) were re-treated with liposomal doxorubicin (Figure 3).  247 
 248 
Most women (84%, n=86/102 with adequate CA-125 data for evaluation) with platinum-249 
sensitive disease had a CA-125 response to second line chemotherapy (complete response 250 
65%, n=66; partial response 19%, n=20) compared to only 32% (n=12/38) of women with 251 
platinum-resistant disease (complete response 11%, n=4; partial response 21%, n=8). Of the 252 
women re-treated with platinum-based agents, 88% (n=79/90) of those who were platinum-253 
sensitive and 54% (n=7/13) of those who were platinum-resistant, had a complete or partial 254 
response. Many of these women also had other agents combined with platinum that they had 255 
not received before. Five of the 7 women with platinum-resistant disease who had a response 256 
were re-treated with platinum plus paclitaxel, docetaxel, gemcitabine or liposomal 257 
doxorubicin. 258 
 259 
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Overall a total of 119 of the 172 women died during the clinical follow-up period; comprising 260 
83 of the 128 women with platinum-sensitive disease and 36 of the 44 women with platinum-261 
resistant disease. Women who had platinum-resistant disease had significantly worse post-262 
progression survival than women who had platinum-sensitive disease (multivariate HR 2.34, 263 
95% CI 1.57-3.49, p<0.001; median post-progression survival 13 versus 30 months). Among 264 
women with platinum-resistant disease, median post-progression survival was 21 months for 265 
the 16 women re-treated with platinum (and 31 months among the 7 women who responded 266 
to re-treatment) versus 10 months for the 28 women not re-treated with platinum.  267 
 268 
Quality of life changes during and after second-line chemotherapy 269 
 270 
Among women with follow-up data and platinum-sensitive disease, 51% (n=49) had an 271 
increase, 40% (n=39) had no meaningful change and 9% (n=9) experienced a decrease in 272 
quality of life over the 6 months after starting second-line chemotherapy. In contrast, among 273 
women with follow-up and platinum-resistant disease, 26% (n=8) had an increase, 42% 274 
(n=13) had no meaningful change and 31% (n=10) reported a decrease in quality of life.  275 
 276 
Group differences in quality of life at chemotherapy initiation 277 
 278 
An unadjusted comparison among women with platinum-resistant disease and follow-up data 279 
indicated that quality of life at chemotherapy initiation was no different in the 10 women who 280 
experienced a decline in quality of life compared to the 21 who had preserved or improved 281 
quality of life (median score 114 vs 112). However, among women with platinum-resistant 282 
disease median quality of life at chemotherapy initiation was higher (median score 121 vs 283 
110) in women whose disease responded to treatment (n=12) compared to women whose 284 
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disease progressed (n=26). 285 
 286 
Platinum status as a predictor of quality of life during and after second-line chemotherapy 287 
 288 
Mixed effects models revealed a clinically meaningful and statistically significant group 289 
improvement in quality of life over the 6 months after starting second-line chemotherapy 290 
among women with platinum-sensitive disease, whereas there was no significant or 291 
precipitate decline among those with platinum-resistant disease (figure 4a). These results 292 
were replicated in sensitivity analyses (figure 4b & 4c). The changes in quality of life over 293 
time were statistically significantly different between the 2 groups in all models (p<0.05). 294 
Current receipt of chemotherapy was the only other factor that was significantly associated 295 
with (decreased) quality of life (p=0.008). Marital status, education level, platinum-based and 296 
liposomal doxorubicin second-line chemotherapy agents were not significantly associated 297 
with quality of life.  298 
 299 
Within the quality of life subscales, a clinically significant but not statistically significant 300 
reduction in physical wellbeing was reported over time in women with platinum-resistant 301 
cancer, whereas a clinically and statistically significant increase in physical and functional 302 
wellbeing and an improvement in ovarian cancer-specific symptoms was reported in women 303 
with platinum-sensitive disease (Figure 5).  304 
 305 
Discussion 306 
 307 
This is the first population-based study to evaluate quality of life separately in women 308 
classified as having platinum-sensitive and platinum-resistant disease. We have shown that, 309 
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overall, among women classified as having platinum-resistant disease, retreatment with 310 
chemotherapy when they experience a recurrence does not significantly improve or diminish 311 
their quality of life. However, one-quarter and one-third of this group respectively report 312 
meaningful increases and decreases in quality of life. Like others [5, 6] we confirmed that for 313 
women with platinum-resistant ovarian cancer, complete tumor response is rare and survival 314 
is significantly poorer than for women with platinum-sensitive disease. Importantly though, a 315 
subset of women with apparently platinum-resistant tumors do respond to re-treatment. 316 
Notably, as reported here and elsewhere [21], the response in women with platinum-resistant 317 
disease appears to be better for those re-treated with platinum-based agents ± other agents 318 
than the response in those re-treated with liposomal doxorubicin or taxane alone. Larger 319 
studies adjusting for characteristics of women selected to receive platinum are needed to 320 
confirm this result and to determine if there is also a quality of life improvement or 321 
maintenance.   322 
 323 
In women with platinum-resistant disease maintenance of quality of life may be a useful 324 
outcome, as there is a possibility that without chemotherapy quality of life would have 325 
rapidly declined due to disease progression. This conclusion however is to be taken with 326 
caution. We were unable to compare the quality of life trajectory of women not given second-327 
line chemotherapy following disease progression since almost all women went on to receive 328 
second-line chemotherapy. We also show that aside from platinum-status the only other 329 
factor that was associated with improved quality of life within our overall sample was 330 
cessation of chemotherapy. Furthermore, our analyses may underestimate decline in quality 331 
of life among women with platinum-resistant disease as computation of missingness in the 332 
mixed effects model is based on the observed data distribution and those women who 333 
dropped out of the study due to incapacity were likely to have poorer quality of life.  334 
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 335 
Our results highlight the need for detailed investigation into which women with platinum-336 
resistant ovarian cancer will and will not benefit from chemotherapy in the later stages of 337 
their disease course. Our preliminary subgroup analysis gives an indication that quality of life 338 
at the start of chemotherapy may be correlated with having a response to treatment. If this 339 
were to be confirmed with a larger sample it is possible that quality of life screening at the 340 
start of treatment may be a useful clinical practice in this particular group of patients. This is 341 
important preliminary information since the decision to re-treat women with platinum-342 
resistant disease may come at considerable cost, both in terms of increased patient morbidity, 343 
and to the health system in terms of expenditure which is estimated at USD $20,744 on 344 
average per woman after first-line chemotherapy [22].  345 
 346 
In conclusion, this study raises important ethical and economic questions about the re-347 
treatment of women with platinum-resistant ovarian cancer with chemotherapy. Disease 348 
response rates are particularly low in those not treated with platinum and approximately one 349 
third of women in the platinum-resistant group when treated with second-line chemotherapy 350 
have significant declines in quality of life. Further research in a larger series of patients with 351 
platinum-resistant disease should be conducted to identify the groups most likely to benefit 352 
from re-treatment with chemotherapy. Given that the majority of women with ovarian cancer 353 
will have a progression and that approximately one-quarter will be classified as having 354 
platinum-resistant disease, evaluation of both the costs and benefits of treating this disease is 355 
essential for efficient use of limited health care resources and optimal patient-centered care 356 
[23].  357 
 358 
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Table 1: Demographic and clinical characteristics of all participants and by missingness 474 
type 475 
 476 
 All 
participants 
(n=172) 
Participants 
with complete 
data (n=104)  
Dropout due 
to death or 
incapacity 
(n=31)  
Dropout due 
to completed 
study or 
unknown 
reason (n=37)  
Platinum sensitive, %  74 77  52*  86 
Age at progression, 
mean (SD)  
60 (10) 60 (9)  62 (10)  58 (12)  
Had partner, %  71 74  53*  76  
Stage III or IV at 
diagnosis, %  
96 96  97  95  
QoL at second-line 
chemotherapy 
initiation, mean (SD)  
105 (22) 108 (22)  96 (22)*  105 (21)  
Survival from second-
line chemotherapy 
initiation (months), 
median  
26 30  9 *  29  
* Different from all participants  477 
  478 
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 493 
 494 
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 497 
 498 
 499 
 500 
 501 
Figure 1. Flow of participant recruitment and data contribution to this analysis 502 
a Completed follow-up for parent study  503 
PROSPECT study  
April 2003 and January 2005 
N = 122 
PROSPECT study 
April 2003 and January 2005 
N = 122 
AOCS-QOL study 
May 2005 and March 2007 
N = 798 
Completed questionnaire within 2 months of 
starting chemotherapy for first progression  
N = 52 
Completed questionnaire within 2 months of 
starting chemotherapy for first progression  
N = 130 
Platinum status was classifiable 
i.e. data used in this analysis N = 172  
Platinum-sensitive (PS) N = 128, 74% 
          Platinum-resistant (PR) N = 44, 26%  
 
3 month follow-up data = 128 (74%)  
• PS withdrawals: death = 7, incapacity = 4, completed follow-upa = 7, unknown = 13. 
• PR withdrawals: death = 4, incapacity = 5, unknown = 4.  
 
6 month follow-up data = 104 (60%) 
• PS withdrawals: death = 2, incapacity = 3, completed follow-upa = 4, unknown = 8. 
• PR withdrawals: death = 4, incapacity = 2, unknown = 1.  
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 505 
Figure 2. Mean quality of life score by dropout time stratified by platinum status   506 
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 519 
Figure 3. Chemotherapy regimen administered after first progression, by platinum 520 
status  521 
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Figure 4a. Least squares mean quality of life scores following second-line chemotherapy in women 
with ovarian cancer treated for platinum-sensitive (n=128) versus -resistant (n=44) disease. Main 
model: including all available data.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4b. Least squares mean quality of life scores following second-line chemotherapy in women 
with ovarian cancer treated for platinum-sensitive (n=112) versus -resistant (n=29) disease. Sensitivity 
model: not including women who dropped out due to death or incapacity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4c. Least squares mean quality of life scores following second-line chemotherapy in women 
with ovarian cancer treated for platinum-sensitive (n=97) versus -resistant (n=31) disease. Sensitivity 
model: not including women with baseline only data.  
  
Note: All models adjusted for age at progression and whether currently on chemotherapy. Marital status, education, second-line chemotherapy 
with platinum or liposomal doxorubicin were tested and not included as covariates due to their lack of association.   
Note: A difference of 8 on the FACT-O scale is considered clinically significant 
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 36 
Figure 5. Wellbeing subscale breakdown of overall quality of life presented in figure 4a.  37 
 38 
Note: A difference of 2 on the wellbeing scales and 2.5 on the ovarian cancer-specific concerns scale is considered to be a 39 
clinically significant least squares mean difference. 40 
 41 
Statistical support (p<0.05) for changes were noted in physical, functional, emotional wellbeing and ovarian cancer-specific 42 
concerns among women who had platinum-sensitive disease.   43 
 44 
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